Abstract
Restless legs syndrome (RLS) is a common and often underestimated neurological disorder, with a prevalence ranging from approximately 2.5% to 10% in Western industrialized countries. The aim of the present study was to summarize the research findings on the human and economic costs associated with RLS in populations without any co-morbidities or potentially confounding health conditions. A further objective was to identify studies on the cost effectiveness of RLS treatments.
A systematic literature search was performed. Two researchers independently assessed the relevance of each publication. Studies published before August 2008 were included if they assessed quality of life in patients suffering from RLS, determined total or patient-related costs attributable to RLS, and/or evaluated the cost effectiveness of treatment options for RLS.
A total of 725 references were identified, including 100 full-text articles. Fifteen of these publications met all of the selection criteria and were included in the present review. Seven abstracts that focused on the economic burden of RLS and/or the cost effectiveness of different treatment strategies in RLS patients were also included.
RLS was associated, in the included studies, with reductions in quality of life similar to those seen in patients with other chronic conditions. The cost-of-illness studies were heterogeneous but indicated that RLS was associated with a substantial economic burden, resulting in high direct and indirect costs to society. Although effective and cost-effective treatments appear to be available, further research is warranted, especially regarding the economic burden of RLS and the cost effectiveness of available treatment options.
Similar content being viewed by others
References
Hornyak M. Restless legs syndrome. Med Welt 2007 Oct; 58 (10): 499–503
Garcia-Borreguero D, Egatz R, Winkelmann J, et al. Epidemiology of restless legs syndrome: the current status. Sleep Med Rev 2006 Jun; 10 (3): 153–67
Jones HJ, Derodra JK. Restless legs syndrome: a review. Euro J Vasc Endovasc Sur 1997 Dec; 14 (6): 430–2
Spiegelhalder K, Hornyak M. Restless legs syndrome in older adults. Clin Geriatr Med 2008 Feb; 24 (1): 167–80
Gomez-Esteban JC, Zarranz JJ, Tijero B, et al. Restless legs syndrome in Parkinson’s disease. Mov Disord 2007 Oct; 22 (13): 1912–6
Suzuki K, Ohida T, Sone T, et al. The prevalence of restless legs syndrome among pregnant women in Japan and the relationship between restless legs syndrome and sleep problems. Sleep 2003 Sep; 26 (6): 673–7
Kavanagh D, Siddiqui S, Geddes CC. Restless legs syndrome in patients on dialysis. Am J Kidney Dis 2004 May; 43 (5): 763–71
Chasens ER. Understanding sleep in persons with diabetes. Diabetes Educ 2007 May; 33 (3): 435–6
Merlino G, Fratticci L, Valente M, et al. Association of restless legs syndrome in type 2 diabetes: a case-control study. Sleep 2007 Jul; 30 (7): 866–71
Manconi M, Fabbrini M, Bonanni E, et al. High prevalence of restless legs syndrome in multiple sclerosis. Eur J Neurol 2007 May; 14 (5): 534–9
Mathis J. Update on restless legs. Swiss Med Wkly 2005 Dec; 135 (47–48): 689–96
Castillo PR, Kaplan J, Lin SC, et al. Prevalence of restless legs syndrome among native South Americans residing in coastal and mountainous areas. Mayo Clin Proc 2006 Oct; 81 (10): 1345–7
Sevim S, Dogu O, Camdeviren H, et al. Unexpectedly low prevalence and unusual characteristics of RLS in Mersin, Turkey. Neurology 2003 Dec; 61 (11): 1562–9
Tan EK, Seah A, See SJ, et al. Restless legs syndrome in an Asian population: a study in Singapore. Mov Disord 2001 May; 16 (3): 577–9
Vignatelli L, Billiard M, Clarenbach P, et al. EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep. Eur J Neurol 2006 Oct; 13 (10): 1049–65
Reese JP, Stiasny-Kolster K, Oertel WH, et al. Health-related quality of life and economic burden in patients with restless legs syndrome. Exp Rev Pharmacoeconomics Outcomes Res 2007 Oct; 7 (5): 503–21
Abetz L, Allen R, Follet A, et al. Evaluating the quality of life of patients with restless legs syndrome. Clin Ther 2004 Jun; 26 (6): 925–35
Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005 Jun; 165 (11): 1286–92
Baggen M, Timmermans M, Moes K, et al. Prevalence and impact of restless legs syndrome (RLS) in primary care. Huisarts Wet 2007 Apr; 50 (4): 134–9
O’Keeffe ST, Egan D, Myers A, et al. The frequency and impact of restless legs syndrome in primary care. Ir Med J 2007; 100 (7): 539–42
Kushida C, Martin M, Nikam P, et al. Burden of restless legs syndrome on health-related quality of life. Qual Life Res 2007 May; 16 (4): 617–24
Happe S, Reese JP, Stiasny-Kolster K, et al. Assessing health-related quality of life in patients with restless legs syndrome. Sleep Med. Epub 2008 Mar 21
Lee HB, Hening WA, Allen RP, et al. Restless legs syndrome is associated with DSM-IV major depressive disorder and panic disorder in the community. J Neuropsychiatry Clin Neurosci 2008 Dec; 20 (1): 101–5
Rothdach AJ, Trenkwalder C, Haberstock J, et al. Prevalence and risk factors of RLS in an elderly population: the MEMO study. Neurology 2000 Mar; 54 (5): 1064–8
Winkelman JW, Finn L, Young T. Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort. Sleep Med 2006 Oct; 7 (7): 545–52
Cuellar NG, Strumpf NE, Ratcliffe SJ. Symptoms of restless legs syndrome in older adults: outcomes on sleep quality, sleepiness, fatigue, depression, and quality of life. J Am Geriatr Soc 2007 Sep; 55 (9): 1387–92
Gerhard R, Bosse A, Uzun D, et al. Quality of life in restless legs syndrome: influence of daytime sleepiness and fatigue. Med Klin 2005 Nov; 100 (11): 704–9
McCrink L, Allen RP, Wolowacz S, et al. Predictors of health-related quality of life in sufferers with restless legs syndrome: a multi-national study. Sleep Med 2007 Jan; 8 (1): 73–83
Phillips B, Young T, Finn L, et al. Epidemiology of restless legs symptoms in adults. Arch Intern Med 2000 Jul; 160 (14): 2137–41
Curtice TG, Long SR, Baser O, et al. Economic burden of restless legs syndrome in a privately-insured population [abstract]. Value Health 2008; 9 (3): A85
Douzinas N, Connolly MP, Kirsch J, et al. Establishing the indirect costs of RLS based on severity using the International Restless Legs Severity rating scale (IRLS) and the productivity and activity impairment [abstract]. Eur J Neurol 2005; 12 (s2): A376
Maurel F, Girard B, Crochard A, et al. Profile of patients suffering from restless legs syndrome and estimation of their annual cost in a ambulatory care setting [abstract]. Value Health 2004; 7 (1): 790–1
Eisensehr I, Möller C, Köster J, et al. Effectiveness of pramipexole in the treatment of RLS and the effect on work productivity: a 12-weeks non-interventional trial in patients with primary restless legs syndrome (RLS) [abstract]. Value Health 2007; 10 (6): A393
Beard AJ. Examination of cost-effectiveness of dopamine agonists for the treatment of restless legs syndrome [abstract]. Value Health 2006; 9 (3): A81
Lees M, Roberts G, Tabberer M, et al. Cost-effectiveness of treating restless legs patients with pramipexole compared to no treatment in Sweden [abstract]. Value Health 2006; 9 (6): A376
Moore AP, Lloyd A, Scott DA, et al. The cost-effectiveness of treating patients with restless legs syndrome (RLS) using ropinirole [abstract]. Value Health 2004; 7 (6): A791
Lees M, Roberts G, Tabberer M, et al. Cost-effectiveness of licensed treatment options for restless legs syndrome in the UK and Sweden. Curr Med Res Opin 2008 Oct; 24 (10): 2919–30
Acknowledgements
The authors thank Matthew D. Gaskins for editing this manuscript. No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Reinhold, T., Müller-Riemenschneider, F., Willich, S.N. et al. Economic and Human Costs of Restless Legs Syndrome. Pharmacoeconomics 27, 267–279 (2009). https://doi.org/10.2165/00019053-200927040-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200927040-00001